Program
ICP-488
A development code. Also written as “ICP-488 Tablets”.
Its studies are mostly in Psoriasis · Lupus Erythematosus, Cutaneous, led by InnoCare Pharma.
Furthest: phase 3, since Feb 18, 20255 company-led studies, 3 open or runningNext primary completion: Mar 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InnoCare Pharma | 53 open or running | phase 3since Feb 18, 2025 | Jun 24, 2022 | Mar 2027phase 2 · NCT07440537 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 24, 2022First study: phase 1 study in PsoriasisFirst studyNCT05451199 · 154 enrolled · China
- Oct 26, 2023Phase 2 study in Moderate to Severe Plaque PsoriasisNCT06109818 · 129 enrolled · China
- Feb 18, 2025Phase 3 study in Plaque Psoriasis PatientsNCT06842199 · 383 planned · China
- Feb 10, 2026Phase 2 study in Lupus Erythematosus, CutaneousNCT07440537 · 105 planned · China
- Jul 21, 2026Phase 2 study in Primary Sjögren's SyndromeNCT07727486 · 240 planned · China
Ahead
- Mar 2027Primary completion: phase 2 study in Lupus Erythematosus, CutaneousNCT07440537
- Dec 2028Primary completion: phase 2 study in Primary Sjögren's SyndromeNCT07727486
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07727486Primary Sjögren's Syndrome · China | 2 | Not yet recruiting | Dec 2028 | 240 |
| NCT07440537Lupus Erythematosus, Cutaneous · China | 2 | Recruiting | Mar 2027 | 105 |
| NCT06842199Plaque Psoriasis Patients · China | 3 | Recruiting | May 2026 | 383 |
| NCT06109818Moderate to Severe Plaque Psoriasis · China | 2 | Completed | Aug 5, 2024 | 129 |
| NCT05451199Psoriasis · China | 1 | UNKNOWN | Oct 30, 2023 | 154 |
How it is read
Names in the registry
- “ICP-488 Tablets”, 5 entries
- “ICP-488”, 1 entry
Codes read as this program: ICP488.
Conditions, from the studies’ own filings
- Psoriasis, 3 studies
- Lupus Erythematosus, Cutaneous, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.